Lynch syndrome.

Lynch syndrome, an inherited DNA mismatch repair–related cancer predisposition, affects about one in 350–450 individuals, but most carriers are undiagnosed, creating a major public health burden.

• Why it matters: Many people with Lynch syndrome remain unidentified despite effective prevention and precision oncology options, and inconsistent implementation plus access inequities limit real-world impact.
• What they did: The Review synthesizes advances including universal tumour testing for MMR deficiency to guide targeted germline testing and cascade screening, alongside preventive strategies such as colonoscopic surveillance, aspirin chemoprevention, and risk-reducing surgery.
• The result: MMR-deficient tumours’ immunogenic biology supports precision treatment, with immune checkpoint inhibitors delivering substantial benefit and vaccine strategies showing promise for cancer interception.

AI summary of the abstract · may contain errors · not medical advice · read the paper.